What is Monte Rosa Therapeutics, Inc.'s deferred revenue?

Monte Rosa Therapeutics, Inc. (GLUE) reported deferred revenue of -$4.21M in Q1 2026.

How has Monte Rosa Therapeutics, Inc.'s deferred revenue changed year-over-year?

Monte Rosa Therapeutics, Inc.'s deferred revenue increased by 95.0% year-over-year, from -$83.94M to -$4.21M.

Monte Rosa Therapeutics, Inc. GLUE Deferred Revenue

Deferred Revenue at other companies

TG TherapeuticsTGTX

——

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.76B+361%

Enterprise value$1.64B+381%

P/S41×+38.6×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInDeferredRevenue.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s deferred revenue?: Monte Rosa Therapeutics, Inc. (GLUE) reported deferred revenue of -$4.21M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s deferred revenue changed year-over-year?: Monte Rosa Therapeutics, Inc.'s deferred revenue increased by 95.0% year-over-year, from -$83.94M to -$4.21M.